Colonis Pharma Successfully Implements Windsor Framework for Medicines
We have successfully implemented the Windsor Framework requirements for human medicines packaging and labelling across all of our products. This achievement ensures that all Colonis UK human medicinal products placed on the UK market from 1st January 2025 have clearly legible ‘UK Only’ text on their packaging. This is to show that they are for sale in the UK and not in EU countries.
Product development at Colonis: Developing value-added medicines for improved patient outcomes
At Colonis Pharma Ltd, we are dedicated to developing treatment options that help improve clinical care and enhance the patient experience. How do we achieve this? Through our streamlined product development process. This process is generally much faster than the traditional drug development route, which involves patient recruitment and clinical trials.
Innovation in value-added medicines
As the healthcare landscape continually evolves, value-added medicines are transforming patient care by taking medicines that already exist and creating innovative solutions that address patient needs. These innovations often lead to better patient outcomes and more convenient treatment options.
Enhancing healthcare logistics with Movianto
Following our recent partnership with Movianto, they have created a case study to showcase exactly how working together has helped to further develop our processes and enhance the delivery of value-added medicines for patients across the UK and beyond.
Enhancing patient care through value-added medicines – innovation and the future
Recognising the value in value added medicines is key to our vision of transforming the future of healthcare. With this in mind, we are pleased to announce that we’ve been accepted as a member of the Medicines for Europe Value Added Medicines Group.
Evolution in the pharmaceutical industry
The world of pharma constantly strives for innovative ways to support patients – it’s part of the very fabric of the industry. Sometimes this involves creating something brand new, but it can also mean working with what already exists and improving it.
Colonis joins the Medicines for Europe Value Added Medicines Group
Recognising the value in value added medicines is key to our vision of transforming the future of healthcare. With this in mind, we are pleased to announce that we’ve been accepted as a member of the Medicines for Europe Value Added Medicines Group.
Colonis Pharma strengthens UK supply chain by entering exciting new collaboration with Movianto
Colonis Pharma, is delighted to announce its new collaboration with Movianto, a leading supply chain solutions partner, to optimize its logistics services for the UK market. The partnership commenced on 1st March, 2024. As a key player in pharmaceutical and healthcare logistics, Movianto offers best-in-class quality, ensuring seamless supply chain management for the delivery of […]
Colonis Pharma Strengthens Longstanding Partnership with Adragos Pharma, Athens
Colonis Pharma, a leading pharmaceutical company focused on innovative value-added medicines, has announced the strengthening of its longstanding partnership with Adragos Athens (formerly known as Lamda Laboratories SA), a specialist in pharmaceutical product development and supply. This move solidifies Colonis Pharma’s commitment to advancing its value-added medicines development portfolio and ensuring the security of its supply […]
Colonis are excited to be attending euroPLX 2024 Lisbon
Suzie Stratford, Alliance and Business Development Manager and Narendra Patel, New Product Business Development Manager are attending euroPLX Lisbon on 26th and 27th of February 2024, and they are interested in meeting with potential partners. If you have a product you would like to launch in the UK or are looking to commercialise any of […]